Harmony Biosciences Q2 revenue rises 30% to $261.3 million; 2026 guidance reiterated
Harmony Biosciences reported second-quarter 2026 net product revenue for WAKIX of $261.3 million, up 30% from $200.5 million a year earlier, and net income of $75.4 million, or $1.28 per diluted share, versus $39.8 million, or $0.68, in the prior-year quarter. The company reiterated its 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion and shared initial Phase 1 single ascending dose data for its orexin-2 agonist BP-205.
Key points
- Net product revenue of $261.3 million, up 30% year over year; estimated average patients rose by 450 to 8,950.
- Net income of $75.4 million, or $1.28 per diluted share, compared with $39.8 million, or $0.68, a year earlier.
- Cost of product sold rose to 24.2% of net product revenue from 19.0%, mainly due to new royalties related to the Novitium license agreement.
- Full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion was reiterated, not changed; cash and investments were $962.5 million as of June 30, 2026.
The filing
Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.